Treatment of autism and similar disorders

a technology for applied in the field of autism and similar disorders, can solve the problems of social deficit, lack of eye contact, and diminished ability to carry on conversation, and achieve the effects of traits associated, reducing the severity of behaviors associated, and increasing the level of oxytocin

Inactive Publication Date: 2006-05-18
NEUROPHARMACOLOGY SERVICES LLC
View PDF6 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] The present invention is directed to the administration of oxytocin, oxytocin analogs and/or combinations thereof to reduce the severity of behaviors and traits associated with autism spectrum disorder. Additionally, the present invention is directed to the administration of oxytocin, oxytocin analogs or combinations thereof to individuals suffering from any disorder that includes repetitive behaviors, social deficits, cognitive deficits, a need to know, a need to order, a need to tell, a need to ask, a self-injurious behavior and a need to touch. The reduction of the severity of behaviors associated with autism upon administration of oxytocin appears unexpected in light of earlier work, which apparently indicated that, while lower levels of oxytocin were present in autistic children when compared to normal patients, among the autistic children, higher levels of oxytocin were

Problems solved by technology

The social deficit dimension involves deficits in reciprocal social interactions, lack of eye contact, diminished ability to carry on conversation, and impaired daily interaction skills.
Autism, outside of its debilitating effect on afflicted individuals, has become an increasing social burden.
Individuals suffering from these disorders further tax the educational and health care systems and are without significant pharmacologica

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of autism and similar disorders
  • Treatment of autism and similar disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

Treatment of Adults with Autistic and Asperger's Disorders with Oxytocin

Experimental Design

[0067] To evaluate the role of oxytocin in treating autism spectrum disorders, fifteen adult patients (mean age=32.9 years, range=19.4-55.6) (14 male, 1 female) diagnosed with autism (N=6) or Asperger's disorder (N=9) received oxytocin and placebo challenges during visits separated by 2-3 weeks to the General Clinical Research Center of the Department of Psychiatry, Seaver Autism Research Center at the Mount Sinai School of Medicine (New York, N.Y.). All patents were carefully evaluated and diagnosed according to both DSM-IV criteria and the Autism Diagnostic Interview-Revised (Lord C, Rutter M, LeCouteur A (1994): Autism Diagnostic Interview-Revised: a revised version of a diagnostic scale for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders 24:659-685.), on which the patients with autism scored within the autistic ra...

example 2

Treatment of Individuals with Asperger's Disorders with Oxytocin and A Psychopharmacologic Agent

[0079] Benefits may be reaped by co-administering oxytocin and a psychopharmacologic agent to patients diagnosed with Asperger's disorder. Oxytocin and the psychopharmacologic agent may be administered in the same infusion mixture. The initial vial of Pitocin® (10 u / mL) and / or valium (10 u / mL) can be combined aseptically with a 1.0 L bag of normal saline and administered at a rate of 10 mL / hr. The infusion can be initiated at a low rate to minimize potential side effects, and the rate gradually titrated up. Specifically, the infusion rate can be titrated every 15 minutes by 25 mL in the first hour, 50 mL in the second hour, 100 mL in the third hour, and then held constant at the maximum rate of 700 mL / hr during the fourth hour. The combined solution, rotated in an infusion bottle to insure thorough mixing, can be added to the system by a constant infusion pump to accurately control the ...

example 3

Treatment of Individuals with Attention Deficiency Disorder (ADD) with Oxytocin

[0081] Individuals with attention deficiency disorder (ADD) can be treated with Oxytocin and or Oxytocin analogs either alone or in combination with another agent as described in Examples 1 and 2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Densityaaaaaaaaaa
Disorderaaaaaaaaaa
Login to view more

Abstract

Methods of treating certain behavioral characteristics associated with autism are provided. Additionally, methods of treating disorders associated with repetitive behaviors, social deficits and/or cognitive deficits are also provided. A therapeutic amount of oxytocin or oxytocin analogs, either alone or in combination, are administered to individuals demonstrating behavioral characteristics associated with autism or other disorders to reduce the severity of the debilitating behavior. In various aspects, characteristics such as deficit in social awareness or cognitive skills and repetitive behaviors are treated. Co-administration of oxytocin and/or oxytocin analogs with known psychopharmacologic agents is also provided. Advantageously, oxytocin and oxytocin analogs do not have deleterious effects with other drugs such that administration results in few side effects.

Description

CROSS REFERENCE TO RELATED APPLICATION [0001] This application claims priority from U.S. Provisional Patent Application No. 60 / 415,837 filed Oct. 3, 2002 entitled, “Treatment of Autism with Oxytocin,” which application is hereby incorporated by this reference in its entirety.FIELD OF THE INVENTION [0002] This invention relates generally to methods of treating autism and any disorder associated with repetitive behaviors, social deficits and / or cognitive deficits. BACKGROUND OF THE INVENTION [0003] Autism is a neurodevelopmental disorder characterized by dysfunction in three core behavioral dimensions: repetitive behaviors, social deficits, and cognitive deficits. The repetitive behavior domain involves compulsive behaviors, unusual attachments to objects, rigid adherence to routines or rituals, and repetitive motor mannerisms such as stereotypies and self-stimulatory behaviors. The social deficit dimension involves deficits in reciprocal social interactions, lack of eye contact, dimi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61BA61K38/00A61K38/095
CPCA61K38/11A61K2300/00A61K38/095A61P25/00
Inventor HOLLANDER, ERIC
Owner NEUROPHARMACOLOGY SERVICES LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap